anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Detrusor overactivity is defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase that may be spontaneous or provoked. Detrusor overactivity is subdivided into idiopathic detrusor overactivity and neurogenic detrusor overactivity The International Continence Society (ICS) defines OAB as the presence of "urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of UTI or other obvious pathology. Neurogenic detrusor overactivity (NDO) can result in lower and upper urinary tract complications and eventually even in end-stage kidney failure. Since the driving force of this clinical cascade is high bladder pressure, controlling intravesical pressure in NDO patients improves both quality of life and life-expectancy in these patients. Botulinum toxin A (BTX-A) has proven its efficacy in reducing intravesical pressure and in reducing incontinence episodes. BTX-A also improves quality of life in patients with NDO. Both onabotulinumtoxinA (Botox®, Allergan, Irvine, USA) and abobotulinumtoxinA (Dysport®, Ipsen, Paris, France) have a level A recommendation for NDO-treatment. The recommended dose for intradetrusor injections in NDO patients is 200 U of onabotulinumtoxinA or 500 U of abobotulinumtoxinA. The drug is generally administered extratrigonal in the detrusor muscle, via cystoscopic guided injection at 20 sites in 1 mL injections. Intradetrusor BTX-A injections are safe, with mostly local complications such as urinary tract infection and high post-void residual or retention. The effect of the toxin lasts for approximately 9 months. Repeat injections can be performed without loss of efficacy. Different injection techniques, novel ways of BTX-A administration, eliminating the need for injection or new BTX-A types with better/longer response rates could change the field in the future. Botulinum toxins are neurotoxins produced by the facultative anaerobe Clostridium botulinum that block the release of acetylcholine into the synaptic gap of the neuromuscular junction. Their injection near the nerves that supply the target organ selectively and temporarily paralyzes the organ. In particular, the subtype botulinum-A toxin is widely used in neurology to release spastic dystonia in adults. and children. In urologic disorders, botulinum-A toxin reliably diminishes external sphincter or detrusor overactivity.
The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
FIELD: chemistry of peptides, medicine. SUBSTANCE: derivatives of nonapeptides of the general formula (I): X-A 1 -A 2 -Trp-Ala-Val-Gly-His-Leu-psi TriQ where Q is OMe, NH 2 ; X is hydrogen, acetyl, CONH 2 ; A 1  is D- or L-Tpi, D-p-Glu; A 2  is Gln, Glu(OMe), Glu(MeNH), Glu, His(Bz) or the formula (II): D-Tpi-A 2 -Trp-Ala-Val-Gly-His-Leu-psiA 9 NH 2  where A 2  is Gln, Glu(OMe), His, His(Bz); A 9  is Leu, Phe, Trp, Trp(For) or their salts with pharmaceutically acceptable acids. Peptides are synthesized by step splicing of peptide chain. Amino-group at α-position is protected and terminal carboxy-group is bound covalently with synthetic polymeric carrier used for this purpose. Then α-protective group is split off, carboxy-group of the next amino acid is reduced to group HC=O and the latter is bound with the above mentioned α-amino-group deblocked preliminary. Then α-amino-protective group of this second amino acid is deblocked and carboxy-group of the next amino acid is bound with above mentioned deblocked α-amino-group of the second amino acid. Then other amino acid are bound to sequence corresponding the structural formula (I) or (II). From obtained peptidylpolymer carrier is split off and if necessary protective groups also. Obtained peptides if necessary are acetylated and the end product is isolated in free form or as a salt with pharmaceutically acceptable acid. Pharmaceutical composition has an active component (compound of the formula I) taken at effective dose and pharmaceutically acceptable carrier. Synthesized compounds show antagonistic activity with respect to bombazine and can be used in medicine for therapy of malignant diseases in animals and human. EFFECT: improved method of synthesis, enhanced effectiveness. 19 cl, 2 tbl, 6 ex
FIELD: microbiology, biotechnology. SUBSTANCE: bacteria are cultured at 35-37 C for 40-50 h at continuous aeration, at medium saturation with oxygen (60-70%) and at stirring at the rate of mixer rotation 250-300 rev/min. Liquid nutrient medium of the following composition is used: enzymatic peptone, magnesium sulfate, potassium dihydrogen phosphate, sodium citrate, copper sulfate, zinc sulfate, iron sulfate, calcium chloride, manganese sulfate, glucose and water. Sowing is carried out with mother exponential culture at amount (1-3) x 10 9  cells/ml. Culturing is carried out for 8-11 h up to the first spores appearance. One-half of cultural fluid of volume reactor is poured out and the same volume of fresh nutrient medium is added. Culturing is continued up to recovery of cell content. Then one-half of cultural fluid of volume reactor is poured out again and the same volume of fresh nutrient medium is added. Then the end product is mixed with biomass stabilizing agent: humin 0.5-2% or sodium sulfite 2-6%. After 10 removal-addition cycles for 40-50 h it is possible to obtain 350-400 l cultural fluid at cell concentration 22-24 billion cells/ml. Cultural fluid containing spore biomass, for example, of the strain B. subtilis-26 and biomass stabilizing agent are used as a bacterial preparation "Phytosporin" in a liquid form. EFFECT: increased output of method, prolonged storage time without lyophilization of a preparation. 1 tbl, 3 ex
AIM: The objective of this study was to create and authenticate a prognostic model for lymph node metastasis (LNM) in colorectal cancer (CRC) that integrates clinical, radiomics, and deep transfer learning features.
MATERIALS AND METHODS: In this study, we analyzed data from 119 CRC patients who underwent F18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scanning. The patient cohort was divided into training and validation subsets in an 8:2 ratio, with an additional 33 external data points for testing. Initially, we conducted univariate analysis to screen clinical parameters. Radiomics features were extracted from manually drawn images using pyradiomics, and deep-learning features, radiomics features, and clinical features were selected using Least Absolute Shrinkage and Selection Operator (LASSO) regression and Spearman correlation coefficient. We then constructed a model by training a support vector machine (SVM), and evaluated the performance of the prediction model by comparing the area under the curve (AUC), sensitivity, and specificity. Finally, we developed nomograms combining clinical and radiological features for interpretation and analysis.
RESULTS: The deep learning radiomics (DLR) nomogram model, which was developed by integrating deep learning, radiomics, and clinical features, exhibited excellent performance. The area under the curve was (AUC = 0.934, 95% confidence interval [CI]: 0.884-0.983) in the training cohort, (AUC = 0.902, 95% CI: 0.769-1.000) in the validation cohort, and (AUC = 0.836, 95% CI: 0.673-0.998) in the test cohort.
CONCLUSION: We developed a preoperative predictive machine-learning model using deep transfer learning, radiomics, and clinical features to differentiate LNM status in CRC, aiding in treatment decision-making for patients.
This group consists of participants diagnosed with Latent Autoimmune Diabetes in Adults (LADA) according to self-reported data. The validation process for this group focuses on assessing the algorithm's ability to accurately identify individuals with LADA, which is often challenging due to its characteristics that overlap with both Type 1 and Type 2 diabetes. Accurate classification of LADA is crucial for improving treatment strategies and understanding its epidemiology.
FIELD: medicine, homeopathy. SUBSTANCE: invention relates to development of complex homeopathic agents for treatment of patients with insomnia and increased excitability state. The agent has Valeriana officinalis C3, Crataegus laevigata C3, Ignatia C6, Leonurus cardiaca C3, Passiflora incarnata C3, Hyoscyamus niger C6, Ambra grisea C6, Bromum C6, Zincum valerianicum C6 being all components are taken at equal parts. The agent can be made in the form of sugar granules. Treatment with the agent results to improvement of the general state, sleep normalization, decrease of nervous excitability and increase of working capacity. EFFECT: enhanced effectiveness. 2 cl, 1 ex
Based on the historical clinical data of more than 1 million pediatric outpatients in the Guangzhou Women and Children's Medical Center, an AI diagnostic framework has recently been developed for common pediatric diseases \[Liang H et al. evaluation and accurate diagnosis of pediatric disease using artificial intelligence. Nat Med. 2019;25(3):433-8\]. This AI framework utilizes predefined schema to extract informative clinical data from free text and reaches clinical diagnoses by hypothetico-deductive reasoning. In internal validation, the AI system showed accuracy rates ranging from 0.85 for gastrointestinal disease to 0.98 for neuropsychiatric disorders, suggesting that it might be a promising assisting diagnostic tool in clinical practice. However, there is a lack of evidence-based strategy on how to handle the scenarios where the AI-based diagnosis and the diagnosis made by pediatricians are discordant. It is legitimate to assume that diseases with discordant diagnoses present more similar clinical features; in this case it is necessary to introduce an extra arbitrator for differential and decisive diagnosis. Therefore, we conduct this randomized controlled trial to: 1) compare the accuracy of the two diagnostic modes in a real-world clinical setting where the AI-based diagnosis and the diagnosis made by pediatricians are discordant by introducing an expert arbitrator; and 2) look further into the change of clinical outcomes (hospital revisit and hospitalization in the next 3 months after initial visit; average total outpatient cost) due to introduction of the expert arbitrator. Please note that although the aforementioned AI framework was designed for diagnosis of a wide range of diseases, this clinical trial is limited to outpatients encountered in three specialty clinics, i.e. respirology, gastroenterology, and genito-urology. The reason for this selection is that the discordant diagnoses are assumed to be more common for these two specialties according to the internal validation result.
Disclosed herein are anti-CD123 nanobodies, a chimeric antigen receptor, and use thereof. The nanobodies are VHH01 and VHH02. The nanobodies VHH01 and VHH02 both have good affinity and specificity for CD123. A chimeric antigen receptor and a chimeric antigen receptor immune cell constructed on the basis of the nanobodies VHH01 and VHH02 both have significant cytotoxicity for CD123-positive cells. Further disclosed herein are a chimeric antigen receptor targeting CD123 and CD7 and use thereof. The chimeric antigen receptor comprises a nanobody VHH01 targeting CD123 and a nanobody VHH10 targeting CD7. The present invention also provides a universal CAR-T cell simultaneously targeting CD123 and CD7, and the CAR-T cell has a significant killing effect on tumor cells.
Participants included in the stable biological cohort must meet criteria for asthma diagnosis. The patients must also be on biological therapy for at least 4 months at enrollment. These participants needed to have an ACT of 20 or greater at time of enrollment, or if ACT 16-19 but they had GINA symptom control level 1-2, then they are considered partly controlled and were included in this group.
Intervention 2, will also be provided with the same 12 week PA program and asked to record their PA while they follow the programme during the 12 week study. The participants in this group will also get support from a physical activity professional (PAP) who will be monitoring their 12 week journey. The PAP will be prompting the participant with weekly information as to why they are doing these exercises as well as supporting the participants to continue their programme as soon as non-adherence to the exercise program becomes apparent during the 12 week study.
Syrian refugee young adults will be trained to implement Problem Management Plus (PM+): a WHO evidence-based low intensity mental health intervention to Syrian refugee adults in their community. They will complete 4 surveys to measure outcomes and mechanisms.
A health search system receives a search query requesting a search for biological information specific to a patient. The health search system accesses a health profile of a patient storing biomarkers determined for the patient. The health search system searches one or more hierarchical data structures to identify one or more health parameters related to the search query where each node of the data structures corresponds to a health parameter belonging to the biological ontology. The health search system determines measurements for one or more biomarkers stored within the health profile of the patient corresponding to the identified health parameters. The health search system generates search results for the search query comprising the identified health parameters and the determined measurements corresponding to each health parameter. The health search system transmits the search results to the user device for display via a graphical user interface.
Physiotherapists will be recruited using the following inclusion criteria: (1) two years of experience in treating patients with chronic pain, (2) currently working in an MSK outpatient clinic and (3) able to read and speak English to a level allowing satisfactory completion of the study procedures. There are no exclusion criterium. Potential participants will be recruited through the relevant gatekeeper. The gatekeeper will be responsible of forwarding the participant information sheet and consent form to the physiotherapists. Physiotherapists will be asked to demonstrate their interest by replying to the email. Any questions will be answered by the research team via email or phone.
Pulmonary resections are performed for a multitude of diagnostic and therapeutic reasons. The last decade has seen a rapid advancement of minimally invasive surgical (MIS) approaches which have resulted in improved patient outcomes. However, the post-operative care pathways have not evolved sufficiently to account for these changes. As such, many patients are still admitted after a minor lung resection for monitoring with a chest tube remaining in situ for a minimum of 24 hours. There have been a few retrospective cohort studies that demonstrate that patients do not experience significant complications during that 24-hour period that would warrant hospitalization. However, there have been no prospective controlled studies evaluating the safety and feasibility of early chest tube removal and discharge after a wedge resection. Furthermore, the maintenance of a large bore chest tube for an extended period is a cause for increased patient discomfort, increased narcotic use and may contribute to chronic pain secondary to intercostal nerve compression. As such, the prolonged chest tube maintenance and hospitalization may overall result in more patient harm than benefit.

Our group recently completed and presented a prospective safety and feasibility study demonstrating that chest tubes can be discontinued as early as 3 hours after minor MIS wedge resections of the lung with no adverse events. This study validated safety criteria that will be implemented moving forward. Furthermore, the maintenance of a large bore chest tube for an extended period is a cause for increased patient discomfort, increased narcotic use and may contribute to chronic pain secondary to intercostal nerve compression. As such, the prolonged chest tube maintenance and hospitalization may overall result in more patient harm than benefit. In the study mentioned previously, early chest tube removal led to 40% more patients being opioid free at post operative day 1 compared to those who underwent routine care.

Nevertheless, it is unclear if patients who undergo more extensive surgeries involving vascular dissection and longer operative times (i.e., pulmonary lobectomies and segmentectomies) will derive the same benefit. The incisions required to complete more complex operations are also larger compared to wedge resections. As such the pain associated with having a chest tube may or may not be as apparent in the setting of the larger incision. It is also unclear what the long-term impact of early chest tube removal has on quality of life in the perioperative period.
The invention discloses a freeze-drying powder injection for treating coronary heart disease and a preparation method thereof. The freeze-drying injection is an improvement of the existing perhexiline injection, with roots of red-rooted salvia and rhizoma ligustici wallichii as main raw materials, and is prepared by mixing and extracting the red-rooted salvia and the rhizoma ligustici wallichii or respectively extracting the red-rooted salvia and the rhizoma ligustici wallichii. The two methods adopt aqueous extract method to extract, precipitating agent to remove impurities and macroporous resin to refine; then filtering and refining; preparing the refined extract and freeze-drying excipient with water for injection into solution, refining, packing, freezing the dried perhexiline freeze-drying powder at a low temperature. Total measurable components of the finished products (Protocatechuicaldehyde, fumalic acid, salvianolic acid B and ligustrazine) are not over 50%, and total purity of phenolic acid is not over 75%. The preparation method of the perhexiline freeze-drying powder has a simple technique and lowers production cost. The perhexiline freeze-drying powder has good stability, high quality, obvious curative effect, convenient storage and other advantages.
At least one non-ionic guar gum and/or at least one cationic modified guar gum is used as sole thickening agent in cosmetic compsns. contg. at least one direct dye and/or at least one pigment and/or at least one oxidn. dye precursor for direct or oxidn. dyeing of keratinic fibres, esp. human hair, without rinsing off.
Several types of evidence suggest that androgens exert clinically significant effects on central nervous system (CNS) function. In animal studies, androgens modulate brain serotonin function, and regulate sexual behavior, aggression, and other non-reproductive behaviors. These actions reflect both organizational and activational effects of androgens. Several studies in humans also support the central modulatory capacity of androgens. Correlative studies have described relationships between plasma androgen levels and sexual interest/behavior and cognitive task performance. Androgens are believed to underlie gender related differences in the prevalence of certain neuropsychiatric disorders, resulting in trials of anti-androgens in at least one of these disorders (Tourette's syndrome). Finally, androgens are believed to possess psychotropic effects in humans, evidenced by purported antidepressant effects and reports of psychotic reactions following administration of androgens. In a recent study, we demonstrated that androgenic/anabolic steroids precipitated mood and behavioral state disturbances when administered in a double-blind, placebo-controlled fashion in normal volunteers. There are remarkably few studies that attempt to identify the CNS effects of androgens or the central systems that may mediate these effects. In this study we propose to examine directly the effects of testosterone on CNS activity by first suppressing and then, in a double-blind, placebo-controlled fashion, replacing physiological levels of testosterone. We will evaluate mood, behavior, cognitive function, physiologic response to serotonergic agonists and cerebral blood flow (separate protocols) during both pharmacologically controlled hormonal conditions: hypogonadism and hypogonadism with testosterone replacement. On the basis of prior findings from our group and from others, we will be asking the following questions: 1) Does cognitive function differ as a function of gender or of hormonal condition; 2) Is the decreased r-CBF that we observed in the prefrontal cortex during the hypogonadal state in women also demonstrable in men; 3) Do measures of hypothalamic-pituitary-adrenal axis responsivity differ as a function of gender or of hormonal condition; and 4) Do CSF neurochemistry and neurosteroid levels differ as a consequence of changing hormonal state. This protocol will not only provide much needed information about the behavioral and physiological effects of androgens but will serve as a companion study for NIMH protocol #92-M-172, "The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism with and without Estrogen and Progressive Replacement."
Pseudomyxoma peritonei (PMP) of pancreatic origin arising from an intraductal papillary mucinous neoplasm (IPMN) is rare. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been established as the optimal treatment for PMP. However, the benefits and safety of CRS with HIPEC for treating PMP of pancreatic origin remain unclear. Herein, we describe a case of PMP of pancreatic origin that was treated with CRS and HIPEC without postoperative complications. A 75-year-old woman was referred to our department. Computed tomography (CT) revealed a multilocular cystic tumor in the pancreatic tail, notable mucinous ascites in the abdominal cavity, and scalloping of the liver and spleen. CT did not reveal the appendix, and the ovaries were normal in size. The patient was diagnosed with PMP of pancreatic origin, and CRS and HIPEC were performed. Intraoperatively, the pancreatic tumor was perforated, and there was a large amount of mucinous ascites. We performed distal pancreatectomy in addition to CRS and HIPEC, with no intraoperative complications. The postoperative course was uneventful, and the patient survived after 6 months without recurrence. CRS with HIPEC may be a feasible treatment option for PMP of pancreatic origin.
First course Course Rituximab at Randomization. Prophylactic 2nd and 3rd course rituximab re-administration will be done at 8 months and 16 months of follow-up if B cell count normalize.
BACKGROUND: Temporomandibular disorders (TMD) are manifested by soreness in the jaw joint area and jaw muscles, clicks or creaks when opening or closing the mouth. All these symptoms can be disabling and occur during chewing and when the patient yawns or speaks. Several classes of drugs are used to treat symptoms. This review aims to assess which drug suits the different signs.
METHODS: Pubmed, Web of Science and Lilacs were systematically searched until 01/02/2023. Clinical trials were selected that dealt with drugs used in temporomandibular dysfunction RESULTS: Out of 830 papers, eight studies were included. The Meta-Analysis with Continuous Outcomes with Pre-Calculated Effect Sizes resulted in the rejection that there is intergroup variability (p.0.74).
CONCLUSIONS: Treatment of orofacial pain is still a significant challenge for dentistry. We can conclude that there is no drug of first choice in the treatment of temporomandibular pain. However, the clinician must distinguish the type of pain and the aetioloic cause of the pain so that the patient can be treated and managed pharmacologically.